Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMandarin In.sg Regulatory News (MDO)

  • This share is currently suspended. It was suspended at a price of 1.65
  • There is currently no data for MDO

Interim Management Statement

18 May 2023 10:23

RNS Number : 8917Z
Mandarin Oriental International Ltd
18 May 2023
 

Announcement

 

The following announcement was issued today to a Regulatory Information Service approved by the Financial Conduct Authority in the United Kingdom.

 

MANDARIN ORIENTAL INTERNATIONAL LIMITED

Interim Management Statement

 

18th May 2023 - Mandarin Oriental International Limited today issues its Interim Management Statement for the first quarter of 2023.

 

The Group recorded an underlying profit in the first quarter of 2023, driven by improved performance from both the Group's owned hotels and its management business. RevPAR grew substantially in Asia compared to last year, as the region benefitted from the removal of travel restrictions. As a result, the Group's owned hotels saw a significantly improved performance, particularly in Hong Kong, Tokyo, and Bangkok. In the rest of the world, our hotels were also able to achieve a higher RevPAR compared to both last year and 2019, driven by strong rates.

 

The first quarter saw progress on a number of hotel developments. In January, the Group announced a new management contract for a luxury beach resort in Mallorca, Spain, scheduled to open by the end of 2024. In February, after three years' work, the Emirates Palace hotel in Abu Dhabi was rebranded as Emirates Palace Mandarin Oriental, Abu Dhabi. In March, Mandarin Oriental, Singapore, closed for a substantial renovation; it is expected to reopen in September 2023.

 

As a result of improved trading conditions, the Group generated underlying earnings before interest, tax, depreciation, and amortisation ('EBITDA') of US$30 million, a substantial increase from the EBITDA loss of US$1 million in the first quarter of 2022. Owned hotels reported an EBITDA of US$19 million, with almost all hotels delivering increased financial performance. The management business saw significant growth and generated higher fees, with hotels, particularly in Hong Kong and Mainland China, contributing to an EBITDA of US$7 million. Unaudited underlying profit in the first quarter was US$3 million, much improved from an underlying loss of US$26 million in 2022.

 

The Group's redevelopment project in Causeway Bay, Hong Kong, formerly the site of The Excelsior hotel, is ongoing, in line with our budget, and is expected to complete in early 2025.

 

Consolidated net debt as at 31st March 2023 reduced to US$311 million (US$376 million at 31st December 2022). The Group's liquidity position remains robust, with US$453 million in available committed debt facilities and US$306 million of cash reserves. Gearing was 6% of adjusted shareholders' funds.

 

On 2nd May 2023, the Company announced that Laurent Kleitman would replace James Riley as Group Chief Executive of Mandarin Oriental International Limited with effect from 1st September 2023.

 

Mandarin Oriental International Limited is incorporated in Bermuda and has a primary listing in the standard segment of the London Stock Exchange, with secondary listings in Bermuda and Singapore. Mandarin Oriental is a member of the Jardine Matheson Group.

 

- end -

 

For further information, please contact:

 

Mandarin Oriental Hotel Group International Limited

James Riley

(852) 2895 9288

Matthew Bishop

(852) 2895 9288

 

Brunswick Group Limited

William Brocklehurst

(852) 5685 9881

 

This and other Group announcements can be accessed online at 'www.mandarinoriental.com'.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DOCKVLBFXELLBBB
Date   Source Headline
19th Jan 20261:45 pmRNSCompletion of Acquisition by Jardine Strategic
16th Jan 20267:00 amRNSCourt Sanction of Scheme of Arrangement
9th Jan 20269:19 amRNSOCB Dividend
31st Dec 20257:22 amRNSUpdate on OCB Sale and Acquisition Timeline
31st Dec 20257:22 amRNSUpdate on OCB Sale and Acquisition Timeline
8th Dec 20253:47 pmRNSResults of Court Meeting & Special General Meeting
21st Nov 20259:58 amRNSInterim Management Statement
14th Nov 202511:37 amRNSReplacement: Publication of Shareholder Circular
14th Nov 20259:38 amRNSAnnouncement (Publication of Shareholder Circular)
17th Oct 202510:24 amRNSRecommended Cash Acquisition of Mandarin Oriental
17th Oct 202510:21 amRNSSale of 301,555 sq.ft. of One Causeway Bay
2nd Oct 202510:20 amRNSDividend Declaration
30th Sep 20257:00 amRNSRESPONSE TO MEDIA SPECULATION
25th Sep 202510:23 amRNSBlock listing Interim Review
28th Jul 202512:33 pmRNSHalf-year Results
11th Jul 202510:28 amRNSNotification to Untraced Shareholders
15th May 202511:44 amRNSINTERIM MANAGEMENT STATEMENT
2nd May 20251:02 pmRNSResult of AGM
30th Apr 202510:24 amRNSDividend Declaration
7th Apr 202510:39 amRNSAnnual Financial Report
25th Mar 20259:20 amRNSBlock listing Interim Review
5th Mar 20251:42 pmRNS2024 PRELIMINARY RESULTS
14th Nov 20249:43 amRNSINTERIM MANAGEMENT STATEMENT
4th Nov 20249:22 amRNSDirectorate Change
2nd Oct 202410:26 amRNSDividend Declaration
25th Sep 202410:19 amRNSBlock listing Interim Review
31st Jul 202410:17 amRNSCompany Board Change
24th Jul 20243:06 pmRNSHalf-year Report
16th Jul 202410:49 amRNSCompany Board Changes
12th Jun 202411:59 amRNSDisposal
23rd May 202410:44 amRNSINTERIM MANAGEMENT STATEMENT
8th May 202412:38 pmRNSResult of AGM
2nd May 202410:23 amRNSDividend Declaration
9th Apr 202410:28 amRNSAnnual Financial Report
25th Mar 20249:26 amRNSBLOCK LISTING INTERIM REVIEW
7th Mar 202410:04 amRNS2023 Preliminary Results
1st Mar 20249:25 amRNSCHANGE OF SINGAPORE BRANCH REGISTRAR
22nd Dec 20231:18 pmRNSMO Signs Option to sell MO, Paris
24th Nov 20239:22 amRNSDirectorate Change
9th Nov 20239:54 amRNSINTERIM MANAGEMENT STATEMENT
27th Sep 202310:28 amRNSDividend Declaration
25th Sep 202310:33 amRNSBlock listing Interim Review
1st Sep 202310:27 amRNSDirector Declaration
28th Jul 202310:33 amRNSHalf-year Results
18th May 202310:23 amRNSInterim Management Statement
4th May 202312:31 pmRNSResult of AGM
2nd May 202310:17 amRNSDirectorate Change
3rd Apr 202310:26 amRNSAnnual Financial Report
31st Mar 202310:24 amRNSTotal Voting Rights
27th Mar 202310:30 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.